BAP1 and cancer: Importantly, IGF-1 levels in carriers with and without a cancer diagnosis did not differ, indicating that significantly increased IGF-1 levels are specific to individuals with SGE-depleted nonsynonymous BAP1 variants rather than a cancer diagnosis, and suggests a possible mechanism of BAP1-mediated pathogenicity (Supplementary Note 2).